The broad goal of this proposal is to develop novel methodologies to achieve site-selective labeling of peptides and peptidomimetics with PET tracers. The novel strategies will be based on the incorporation of bioorthogonally labeled unnatural amino acids via solid phase peptide synthesis protocols. The resulting radiolabeled peptides will be evaluated in parallel, and hit candidates further tested in animal imaging experiments. The candidate, Thomas Reiner, has extensive experience in the quantitative sciences, specifically synthetic organometallic and organic chemistry. He has worked on bioorthogonal strategies before. He will apply his skillset to this translational approach, which i at the interface of organic synthesis, biology and biomedical imaging. The successful development of techniques and protocols which allow site-selective incorporation of bioorthogonal labels into peptides, as well as the parallelized evaluation of their corresponding radiolabeled versions will represent a major step in biomedical imaging research, greatly facilitating design, evaluation, and ultimately clinical translation of diagnosic radiolabeled probes. The long term goal of the candidate is to develop novel and more efficient methodologies which allow conjugation of PET labeled imaging agents to targeted biomolecules. This work will be performed at the Department of Radiology of Memorial Sloan-Kettering Cancer Center under the mentorship of Dr. Jason Lewis. Both Dr. Hedvig Hricak and Dr. Wolfgang Weber, who are experts in preclinical and clinical imaging research, will serve as co-mentors. The members of the advisory committee are fully committed to the mentored research training of the candidate, allowing him to develop a strong and successful career as an independent biomedical researcher.
The specific aims of this proposal are to first synthesize tetrazine and trans-cyclooctene amino acids, followed by their incorporation into somatostatin-analogs, generating a library of bioorthogonally labeled peptides. Then, these peptides will be converted into their corresponding 18F, 89Zr and 64Cu labeled versions by utilizing parallel bioorthogonal assembly and purification techniques. High affinity and selectivity peptides will subsequently be tested in animal models of cancer. Here, tetrazine and trans-cyclooctene amino acids will not only allow the fast and selective synthesis, but also the rapid chromatography free purification of radiolabeled peptides, facilitating multiplexed parallel synthesis of radiolabeled peptide libraries. Hit candidates will be evaluated for their performance as targeted probes in animal models of cancer. If successful, these new technologies will allow the rational and high-throughput evaluation of targeted peptidic PET probes, streamlining their development and increasing the chances of successful outcomes. The design of radiolabeled targeted peptides via tetrazines/trans-cyclooctenes could become a standard technique for preclinical biomedical imaging and ultimately clinical research.

Public Health Relevance

This project aims to create novel methodologies to achieve site-selective radiolabeling of peptides using bioorthogonal chemistries. If successful, libraries f peptides conjugated to different PET isotopes will be tested in vitro in a high throughput screen, and hit candidates further evaluated in small animal imaging experiments. Ultimately, such a technique will decrease the development time of potential clinical candidates and thus increase the likelihood of successful translation to the clinic.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Mentored Quantitative Research Career Development Award (K25)
Project #
1K25EB016673-01
Application #
8487906
Study Section
Special Emphasis Panel (ZEB1-OSR-B (J2))
Program Officer
Erim, Zeynep
Project Start
2013-04-01
Project End
2016-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
1
Fiscal Year
2013
Total Cost
$174,906
Indirect Cost
$12,956
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Tang, Jun; Baxter, Samantha; Menon, Arjun et al. (2016) Immune cell screening of a nanoparticle library improves atherosclerosis therapy. Proc Natl Acad Sci U S A 113:E6731-E6740
Büchel, Gabriel E; Carney, Brandon; Shaffer, Travis M et al. (2016) Near-Infrared Intraoperative Chemiluminescence Imaging. ChemMedChem 11:1978-82
Kossatz, Susanne; Brand, Christian; Gutiontov, Stanley et al. (2016) Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. Sci Rep 6:21371
Pérez-Medina, Carlos; Binderup, Tina; Lobatto, Mark E et al. (2016) In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models. JACC Cardiovasc Imaging 9:950-61
Pérez-Medina, Carlos; Abdel-Atti, Dalya; Tang, Jun et al. (2016) Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy. Nat Commun 7:11838
Kossatz, Susanne; Weber, Wolfgang A; Reiner, Thomas (2016) Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma. PLoS One 11:e0147752
Meyer, Jan-Philip; Houghton, Jacob L; Kozlowski, Paul et al. (2016) (18)F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry. Bioconjug Chem 27:298-301
Carney, Brandon; Carlucci, Giuseppe; Salinas, Beatriz et al. (2016) Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models. Mol Imaging Biol 18:386-92
Salinas, Beatriz; Irwin, Christopher P; Kossatz, Susanne et al. (2015) Radioiodinated PARP1 tracers for glioblastoma imaging. EJNMMI Res 5:123
Carlucci, Giuseppe; Carney, Brandon; Brand, Christian et al. (2015) Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma. Mol Imaging Biol 17:848-55

Showing the most recent 10 out of 18 publications